Altimmune Welcomes New Board Members Teri Lawver and Jerry Durso
In a significant step forward for Altimmune, a clinical-stage biopharmaceutical company, Teri Lawver and Jerry Durso have been appointed to its Board of Directors. This strategic enhancement is set to bolster the company as it progresses into the late-stage clinical development of pemvidutide, a promising therapeutic candidate.
Expertise of Teri Lawver
Teri Lawver brings a wealth of experience to the board, having spent nearly 30 years in various leadership roles in the healthcare sector. Her most recent position was as Executive Vice President and Chief Commercial Officer at Dexcom, where she played a pivotal role in shaping global commercial strategies. At Johnson & Johnson, she held influential positions that significantly impacted cardiovascular and metabolic health sectors.
Her extensive background also includes developing innovative treatments that have transformed patient care. Lawver’s involvement in managing Janssen's substantial immunology portfolio—valued at $16 billion—demonstrates her capability in overseeing critical product launches and navigating complex market dynamics.
Jerry Durso’s Strategic Leadership
Alongside Lawver, Jerry Durso joins the board with over 30 years of experience in the biopharmaceutical industry. His most recent leadership role was as CEO of Intercept Pharmaceuticals, where he successfully built a business focused on rare liver diseases, culminating in a strategic acquisition.
Durso's previous experiences at Sanofi, where he led multiple high-profile franchises in diabetes and cardiovascular care, reflect his strong commercial acumen and deep understanding of the commercial landscape. His ability to combine clinical insights with market strategies will be essential as Altimmune navigates the complexities of bringing pemvidutide to market.
Aligning with Corporate Strategy
Vipin K. Garg, Ph.D., Altimmune's President and CEO, expressed his enthusiasm regarding the new board members, highlighting how Lawver and Durso’s diverse expertise will guide the company's vision. Their backgrounds are not only complementary but also crucial as Altimmune prepares for pemvidutide's transition toward commercial viability.
Pemvidutide and its Potential Impact
Pemvidutide represents a novel approach in treating obesity and metabolic diseases, leveraging dual receptor agonist technology. This innovative product aims to produce significant benefits, including liver health improvement and effective weight management. With the insights of Lawver and Durso, Altimmune expects to accelerate its journey towards successful commercialization.
About Altimmune
Altimmune, a clinical-stage biopharmaceutical company, is committed to pioneering next-generation peptide-based therapeutics. Currently, their primary focus is on pemvidutide, a treatment poised to address critical health challenges associated with obesity and liver diseases. As part of their growth strategy, they are developing cutting-edge solutions that have the potential to transform patient outcomes.
Frequently Asked Questions
What is Altimmune's primary focus?
Altimmune is focused on developing innovative peptide-based therapeutics, specifically targeting obesity and liver diseases.
Who are the new board members of Altimmune?
Teri Lawver and Jerry Durso have recently joined Altimmune's Board of Directors, bringing extensive biopharmaceutical experience.
What is pemvidutide?
Pemvidutide is a GLP-1/glucagon dual receptor agonist being developed for the treatment of obesity and liver conditions.
Why are the new board members significant?
Their expertise in commercialization and corporate strategy will be invaluable in guiding Altimmune towards successful product launches.
How does Altimmune plan to advance pemvidutide?
Altimmune plans to leverage the experience of its new board members to enhance its clinical development and transition towards commercialization.
